Fig. 3: Incidence of HF events according to S100A8/A9 levels and S100A8/A9 genetic score.

Kaplan–Meier curves illustrate the timing of HF events in the four strata of S100A8/A9 levels and S100A8/A9 genetic score. The quartile of S100A8/A9 (ng/ml) was used to classify patients into four risk categories, including low, low-intermediate, intermediate-high, and high-risk in the discovery cohort (a) and validation cohort (b). Similarly, the quartile of the S100A8/A9 genetic score was used to classify patients in the validation cohort into four risk categories (c). The vertical black dashed line means the median follow-up time (4.2 and 2.9 years for discovery and validation cohorts respectively). The maximum follow-up time is 5.8 years and 5.3 years for discovery and validation cohorts respectively. P-values reported are two-tailed from log-rank tests. P < 0.05 was considered as significant. Source data are provided in the Source Data File.